Department of Non-Communicable Diseases and Injuries, Santé Publique France, The National Public Health Agency, Saint-Maurice, France.
Institute of Psychiatry and Neurosciences, Team 1, Université Paris Cité, INSERM UMR1266, Paris, France.
Eur Psychiatry. 2023 Dec 13;67(1):e1. doi: 10.1192/j.eurpsy.2023.2473.
To assess the associations between anxiety and depressive symptoms and post-COVID-19 condition (PCC) by exploring the direction of these associations and their relevance in the definition of PCC.
Nationwide survey among French adults, recruited between March and April, 2022, using a quota method to capture a representative sample of the general population with regard to sex, age, socioeconomic status, size of the place of residence, and region. We included all participants who met the World Health Organization (WHO) definition of PCC in addition to a random sample of participants infected with SARS-COV-2 for at least 3 months but without PCC. Self-reported anxiety and depressive symptoms, chronic anxiety and depression (for more than 3 years), and anxiety and depression were measured using the GAD-2 and PHQ-2 questionnaires, respectively.
In a sample of 1,095 participants with PCC and 1,021 participants infected with SARS-COV-2 without PCC, 21% had self-reported anxiety and 18% self-reported depression, whereas 33% and 20% had current measured symptoms of anxiety and depression, respectively. The high prevalence of these symptoms cannot only be explained by the characterization of PCC, as only 13.4% of anxiety symptoms and 7.6% of depressive symptoms met the WHO criteria for PCC. Only one participant met the WHO criteria based on self-reported anxiety or depressive symptoms alone, as these were always combined with other symptoms in patients with PCC. Chronic symptoms were associated with PCC (aOR 1.27; 95% CI: 1.00-1.61). In addition, measured anxiety was associated with PCC (aOR = 1.29; 95% CI: 1.02-1.62).
Pre-COVID-19 chronic anxiety and depression may play a role in the development of PCC or share vulnerability factors with it. Our results challenge the inclusion of anxiety and depression in the definition of PCC.
通过探讨这些关联的方向及其在 PCC 定义中的相关性,评估焦虑和抑郁症状与新冠后疾病(PCC)之间的关联。
这是一项在法国成年人中进行的全国性调查,于 2022 年 3 月至 4 月期间采用配额法招募参与者,以捕获具有代表性的普通人群样本,样本涵盖性别、年龄、社会经济地位、居住地规模和地区。我们纳入了符合世界卫生组织(WHO)PCC 定义的所有参与者,以及至少感染 SARS-CoV-2 3 个月但没有 PCC 的随机参与者样本。使用 GAD-2 和 PHQ-2 问卷分别测量了自我报告的焦虑和抑郁症状、慢性焦虑和抑郁(超过 3 年)以及焦虑和抑郁。
在一个有 PCC 的 1095 名参与者和一个没有 PCC 的感染 SARS-CoV-2 的 1021 名参与者的样本中,21%的人自我报告有焦虑,18%的人自我报告有抑郁,而分别有 33%和 20%的人有当前测量的焦虑和抑郁症状。这些症状的高患病率不仅可以用 PCC 的特征来解释,因为只有 13.4%的焦虑症状和 7.6%的抑郁症状符合 PCC 的 WHO 标准。只有一名参与者符合 WHO 基于自我报告的焦虑或抑郁症状的标准,因为这些症状在 PCC 患者中总是与其他症状相结合。慢性症状与 PCC 相关(OR 1.27;95%CI:1.00-1.61)。此外,测量的焦虑与 PCC 相关(OR=1.29;95%CI:1.02-1.62)。
COVID-19 前的慢性焦虑和抑郁可能在 PCC 的发展中起作用,或者与 PCC 共享脆弱性因素。我们的结果对将焦虑和抑郁纳入 PCC 的定义提出了挑战。